Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Klaria Pharma Holding

0.52 SEK

+5.69 %

Less than 1K followers

KLAR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+5.69 %
+0.39 %
-14.47 %
+15.97 %
+59.24 %
+38.56 %
-61.73 %
-91.33 %
-88.62 %

Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapeutic areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of an alginate-based polymer film. The film is attached to the patient's oral mucosa, which enables the distribution of drugs in the body. The headquarters are located in Uppsala.

Read more
Market cap
127.91M SEK
Turnover
176.56K SEK
Revenue
2.25M
EBIT %
-1,387.11 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.2
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release11/26/2025, 4:00 PM

Klaria Pharma Holding AB: Klaria Interim Report Q3 2025

Klaria Pharma Holding
Regulatory press release8/28/2025, 6:30 AM

Klaria Pharma Holding AB: Klaria Interim Report Q2 2025

Klaria Pharma Holding
Regulatory press release7/3/2025, 8:30 AM

Klaria Pharma Holding AB: Klaria stengthens patent portfolio of sumatriptan alginate film with new filing

Klaria Pharma Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/21/2025, 2:16 PM

Klaria Pharma Holding AB: Klaria Interim Report

Klaria Pharma Holding
Regulatory press release4/30/2025, 9:00 AM

Klaria Pharma Holding AB: Klaria Annual Report 2024

Klaria Pharma Holding
Press release2/28/2025, 4:38 PM

Redeye: Klaria Pharma Q4 - Transforming licensing deal

Klaria Pharma Holding
Regulatory press release2/28/2025, 9:10 AM

Klaria Pharma Holding AB: Klaria Year-End Report 2024

Klaria Pharma Holding
Press release1/15/2025, 7:41 AM

Redeye: Klaria Pharma - Licensing deal with CNX Therapeutic

Klaria Pharma Holding
Regulatory press release1/10/2025, 6:00 PM

Klaria Pharma Holding AB: Klaria signs license agreement for Sumatriptan Alginate film in Europe with CNX Therapeutics

Klaria Pharma Holding
Press release11/22/2024, 9:24 AM

Redeye: Klaria Pharma Q3 - Awaiting business developments

Klaria Pharma Holding
Regulatory press release11/21/2024, 2:00 PM

Klaria Pharma Holding AB: Klaria Interim Report Q3 2024

Klaria Pharma Holding
Press release8/23/2024, 6:35 AM

Redeye: Klaria Pharma Q2 - Defining Chapter Approaches

Klaria Pharma Holding
Regulatory press release8/22/2024, 2:00 PM

Klaria Pharma Holding AB: Klaria Interim Report Q2 2024

Klaria Pharma Holding
Regulatory press release8/14/2024, 6:30 AM

Klaria Pharma Holding AB: Klaria Sumatriptan Alginate Film Receives Marketing Authorization

Klaria Pharma Holding
Press release5/17/2024, 5:48 AM

Redeye: Klaria Pharma Q1 - Crucial period ahead

Klaria Pharma Holding
Regulatory press release5/16/2024, 9:37 AM

Klaria Pharma Holding AB: Klaria Interim Report Q1 2024

Klaria Pharma Holding
Press release3/1/2024, 3:00 PM

Redeye: Klaria Pharma Q4 - Eyes on the prize

Klaria Pharma Holding
Regulatory press release2/29/2024, 3:30 PM

Klaria Pharma Holding AB: Klaria Year-End Report 2023

Klaria Pharma Holding
Regulatory press release2/26/2024, 11:27 AM

Klaria Pharma Holding AB: Klaria accelerates its business development efforts

Klaria Pharma Holding
Press release11/27/2023, 7:19 AM

Redeye: Klaria Pharma Q3 2023 - Take-off is on the horizon

Klaria Pharma Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.